Objective: to assess the acute toxicity of pyrimidine derivative 2-Methyl-3-(2-phenyl-2-oxoethyl)quinazoline-4(3H)-oh. Materials and methods. The study was conducted on 20 non-linear rats (females) weighing from 180 to 200 g 2 months of age. In the experiment, the rats were divided into several groups: the control group received an intragastric equiobjection of distilled water; the experimental group received an intragastric pyrimidine compound at a dose of 2000 mg/kg in the form of a suspension. Observation was carried out for each animal separately: 30 minutes after administration; every 4 hours on the first day; then daily for 14 days. The general condition of the animals, body weight, skin and coat condition, respiratory, cardiovascular and nervous systems were assessed. After removal from the experiment, internal organs were examined in all animals, hematological (total blood count and hemoglobin concentration) and biochemical parameters (total protein, total bilirubin, alanine aminotransferase, aspartate aminotransferase, creatinine, urea) were evaluated. The results of the study. With the introduction of pyrimidine derivative 2-Methyl-3-(2-phenyl-2-oxoethyl)quinazolin-4(3H)-oh at a dose of 2000 mg/ kg, there were no changes in the skin and coat, as well as mucous membranes during the entire observation period; there was a decrease in the body weight of animals on the first day by 14 % (p ≤ 0,05); during macroscopic analysis of internal organs (brain, stomach liver, kidneys), there was no increase in their mass, hyperemia and hemorrhages; no changes in hematological and biochemical parameters were observed. Conclusion. Thus, in determining the acute toxicity of pyrimidine derivative 2-Methyl-3-(2-phenyl-2-oxoethyl)quinazolin-4(3H)-oh in the limit test, it was found that the specified compound is slightly toxic and belongs to the 4th class of toxicity. To exclude the presence of organotoxicity of this compound, it is necessary to conduct further detailed studies with prolonged administration of this pyrimidine derivative.
pyrimidine derivatives, acute toxicity, organotoxicity
1. Abdellatif K. R., Bakr R. B. Pyrimidine and fused pyrimidine derivatives as promising protein kinase inhibitors for cancer treatment // Medicinal Chemistry Research. 2021. Vol. 30, no. 1. P. 31-49. doihttps://doi.org/10.1007/s00044-020-02656-8.
2. Verma V., Joshi C. P., Agarwal A., Soni S., Kataria U. A review on pharmacological aspects of pyrimidine derivatives // Journal of Drug Delivery and Therapeutics. 2020. Vol. 10, no. 5. P. 358-361. doi:https://doi.org/10.22270/jddt.v10i5.4295.
3. Zarenezhad E., Farjam M., Iraji A. Synthesis and biological activity of pyrimidines-containing hybrids: Focusing on pharmacological application // Journal of Molecular Structure. 2021. Vol. 1230. P. 129833. doi:https://doi.org/10.1016/J.MOLSTRUC.2020.129833.
4. Löffler M., Carrey E. A., Zameitat E. New perspectives on the roles of pyrimidines in the central nervous system // Nucleosides, Nucleotides and Nucleic Acids. 2018. Vol. 37, no. 5. P. 290-306. doi:https://doi.org/10.1080/15257770.2018.1453076.
5. Samotrueva M. A., Ozerov A. A., Starikova A. A., Gabitova N. M., Merezhkina D. V., Cibizova A. A., Tyurenkov I. N. Izuchenie antimikrobnoy aktivnosti novyh hinazolin-4(3n)-onov po otnosheniyu k Staphylococcus aureus i Streptococcus pneumoniae // Farmaciya i farmakologiya. 2021. T. 9, № 4. S. 318-329. doi:https://doi.org/10.19163/2307-9266-2021-9-4-318-329.
6. Cibizova A. A., Ozerov A. A., Novikov M. S., Samotrueva M. A., Yasenyavskaya A. L., Tyurenkov I. N. Sintez i immunotropnaya aktivnost' novyh proizvodnyh hinazolina u myshey // Himiko-farmacevticheskiy zhurnal. 2020. T. 54, № 10. S. 26-29. doi:https://doi.org/10.30906/0023-1134-2020-54-10-26-29.
7. Tyurenkov I. N., Cibizova A. A., Samotrueva M. A., Ozerov A. A. Immunotropnye svoystva karbonil'nogo proizvodnogo hinazolina // Astrahanskiy medicinskiy zhurnal. 2017. T. 12, № 2. S. 81-88.
8. Geyn V. L., Prudnikova A. N., Kurbatova A. A., Rudakova I. P. Anal'geticheskaya aktivnost' i ostraya toksichnost' proizvodnyh digidrotetrazolo[1,5-a]pirimidina // Himiko-farmacevticheskiy zhurnal. 2021. T. 55, № 3. S. 19-21. doi:https://doi.org/10.30906/0023-1134-2021-55-3-19-21.
9. Oficerova E. S., Alekseeva L. N., Shklyarenko A. A., Yakovlev I. P. Biologicheskaya aktivnost' novyh 6-[(1-naftilmetil)tio]-4-hlorpirazolo[3,4-d]pirimidinov // Aspirantskiy vestnik Povolzh'ya. 2020. № 1-2. S. 146-151. doi:https://doi.org/10.17816/2072-2354.2020.20.1.146-151.
10. Kuvaeva E. V., Kolesnik D. A., Levshukova P. O. Ocenka protivovospalitel'noy aktivnosti novogo proizvodnogo 1,6-digidropirimidina // Farmaciya. 2021. T. 70, № 4. S. 44-47. doi:https://doi.org/10.29296/25419218-2021-04-07.
11. Oficerova E. S., Alekseeva L. N., Shklyarenko A. A., Yakovlev I. P. Biologicheskaya aktivnost' novyh 1-benzoilzameschennyh-6-(metiltio)-4-hlor-1N-pirazolo [3, 4-d] pirimidinov // Medicina. 2020. T. 8, № 3. S. 76-84.
12. Kuvaeva, E. V., Ladut'ko, Yu. M., Kolesnik, D. A., Levshukova, P. O., Fedorova, E. V. Sintez i opredelenie aktivnosti novogo proizvodnogo gidroksioksopirimidina - potencial'nogo ob'ekta dlya izgotovleniya protivovospalitel'nogo gelya // Journal of Siberian Medical Sciences. 2022. T. 6, № 1. S. 46-55.
